Connect Biopharma Holdings Ltd(CNTB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.2 | Insider Own | 72.85% | Shs Outstand | 63.0M | Perf Week | 9.62% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | 24.12% | Insider Trans | 0.33% | Shs Float | 17.1M | Perf Month | -24.05% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.26 | Inst Own | 27.3% | Short Float | 22.56% | Perf Quarter | -58.64% |
| Income | -0.07B | P/S | 17.83 | EPS this Y | 2.49% | Inst Trans | 5.5% | Short Ratio | 0.99 | Perf Half Y | -66.18% |
| Sales | 0.00B | P/B | 1.96 | EPS next 5Y | 7.93% | ROA | -109.34% | Short Interest | 3.86M | Perf YTD | -70.38% |
| Book/sh | 0.43 | P/C | 1.67 | EPS past 3/5Y | 22.61% 12.68% | ROE | -140.51% | 52W High | -78.13% ($3.82) | Perf Year | -47.24% |
| Cash/sh | 0.5 | P/FCF | - | Sales past 3/5Y | - | ROIC | -254.92% | 52W Low | 14.15% ($0.73) | Perf 3Y | -35.25% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -322.65% | Gross Margin | - | Volatility(W/M) | 7.92% 9.27% | Perf 5Y | -94.73% |
| Dividend TTM | - | EV/Sales | 7.36 | Sales Y/Y TTM | - | Oper. Margin | -2384.49% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.37 | EPS Q/Q | -18.29% | Profit Margin | -2336.3% | RSI (14) | 34.87 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.37 | Sales Q/Q | 5666.67% | SMA20 | -4.23% ($0.88) | Beta | 0.02 | Target Price | $5.91 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/12 | SMA50 | -39.84% ($1.4) | Rel Volume | 0.06 | Prev Close | $0.85 |
| Employees | 64 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 14.5% 271.31% | SMA200 | -62.05% ($2.21) | Avg Volume(3M) | 3.90M | Price | $0.84 |
| IPO | 2021/3/19 | Option/Short | Yes/Yes | Trades | 689 | Volume | 248,588 | Change | -1.17% |
💊 Connect Biopharma is a clinical-stage biopharmaceutical company developing therapeutics for inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The company is focused on developing novel antibodies that target immune-inflammatory pathways, with its lead candidate rademikibart at the center of this effort, and is advancing its clinical development through global partnerships.
Over the past 1 year, on the lower side
78% below its 1-year high.
Traded less than usual. That is 6% of its average volume.
CNTB has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +2.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,783. Peers typically go for $1,089.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
22.6% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #414 of 594 in the industry
Based on market cap of $53M.
HOWL#411 Werewolf Therapeutics Inc $53M PER - 
ELOX#412 Eloxx Pharmaceuticals Inc $53M PER - 
PLRX#413 Pliant Therapeutics Inc $53M PER - CNTB#414 Connect Biopharma Holdings Ltd $53M PER - 
GANX#415 Gain Therapeutics Inc $52M PER - 
FAQ
What kind of company is CNTB?
CNTB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CNTB?
The market cap of CNTB is approximately $53M, ranking 4,829 within its sector.
What is the 52-week high and low for CNTB?
CNTB has recorded a 52-week high of $3.82 and a low of $0.73.
